Summary
Guardant Health, Inc. (GH) announced updates to the compensation arrangements for its Co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, effective January 1, 2024. The company has entered into new letter agreements that primarily adjust the incentive compensation structure, moving away from traditional salaries and cash bonuses towards equity awards. This move signals a continued focus on aligning executive compensation with long-term company performance and shareholder value creation. Key changes include maintaining a nominal base salary of $1 per year, with future salary adjustments to be determined by the Compensation Committee. Instead of salary and annual bonuses, each Co-CEO will receive annual grants of Restricted Stock Units (RSUs) and Performance-based RSUs (PSUs) valued at $800,000. Additionally, they will receive significant long-term awards of RSUs and PSUs valued at $5,000,000 each, tied to multi-year performance metrics. The cancellation of prior PSU awards is also noted. These adjustments underscore a strong emphasis on performance-driven incentives and long-term commitment from the leadership team.
Key Highlights
- 1Co-CEOs Helmy Eltoukhy and AmirAli Talasaz have new compensation agreements effective January 1, 2024.
- 2Base salaries are reduced to $1 annually, with future adjustments subject to the Compensation Committee.
- 3Annual equity awards of $800,000 (in RSUs and PSUs) will replace base salary and annual cash bonuses.
- 4RSUs vest over one year, while PSUs are earned based on annual performance goals and vest upon bonus payment to other executives.
- 5Significant long-term equity awards of $5,000,000 each (in RSUs and PSUs) have been granted.
- 6Long-term PSUs are tied to 3-year performance metrics including Revenue CAGR, relative TSR, and absolute TSR.
- 7Prior PSU awards granted in May 2020 have been cancelled.